The growing prevalence of cancer creates a higher demand for effective treatment options. Tumor ablation techniques offer a minimally invasive alternative to traditional surgery to treat solid tumors. As cancer rates continue to rise, there is an increasing need for treatments that can effectively target and destroy tumors, leading to the growth of the tumor ablation market.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-tumour-ablation-market
Tumor ablation procedures are particularly valuable for patients with inoperable tumors. These may include tumors in critical or hard-to-reach areas or cases where surgery carries a higher risk due to the patient's overall health condition. Tumor ablation provides a viable treatment option for such patients, allowing tumor destruction without major surgery.
For instance,
- In 2020, WHO reported that cancer is a leading cause of morbidity and mortality worldwide, with approximately 19.3 million new cancer cases and 10 million cancer-related deaths
- As per IARC (International Agency for Research on Cancer), colorectal cancer is the third most commonly diagnosed worldwide. In 2020, there were approximately 1.9 million new cases of colorectal cancer globally
Moreover, the rising prevalence of cancer drives the demand for tumor ablation procedures as an effective and minimally invasive treatment option. The need to address the growing incidence of cancer, coupled with advancements in imaging technologies and the preference for less invasive procedures, fuels the growth of the tumor ablation market.
Data Bridge Market Research analyses that the Global Tumor Ablation Market is expected to grow at a CAGR of 13.8% in the forecast period of 2023 to 2030 and is expected to reach USD 4,225.84 million by 2030. The rising technological advancements is projected to propel the growth of the market.
Key Findings of the Study
Increasing inclination of surgeons and patients toward minimally invasive procedures
Minimally invasive procedures involve smaller incisions or needle insertions than traditional open surgeries. This results in less tissue damage, reduced blood loss, and lower risk of complications. These procedures typically have shorter hospital stays and faster recovery times. Patients can often resume their normal activities sooner, improving their quality of life.
Minimally invasive techniques often employ advanced imaging technologies, allowing surgeons to visualize and precisely target tumors. This enhances accuracy and helps preserve healthy surrounding tissues. The instruments are designed to provide greater maneuverability and agility, enabling surgeons to perform complex procedures with improved control and precision. The procedures involve smaller incisions, which reduces the risk of post-operative infections compared to open surgeries.
For instance,
- A study published in the journal European Urology Focus in 2020 reported the growing utilization of HIFU as an alternative to surgery or radiation therapy for prostate cancer treatment
- A study published in the Journal of Thoracic Disease in 2019 examined the utilization of Microwave Ablation (MWA) for treating lung tumors. The authors reported an increasing trend in using MWA as a minimally invasive alternative to surgery for lung tumors. The study emphasized the benefits of MWA in terms of reduced hospital stays, shorter recovery times, and better preservation of lung function
The increasing inclination of surgeons and patients towards minimally invasive procedures such as tumor ablation is driven by the desire for improved patient outcomes, faster recovery, and reduced healthcare costs. This trend has propelled the growth of the global tumor ablation market, leading to increased adoption and advancements in minimally invasive techniques.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2015 to 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Type (Thermal Ablation and Chemical Ablation), Types of Treatment (Percutaneous, Laparoscopic, and Surgical), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Bone Cancer, and Others), End Users (Hospitals, Oncology Centers, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Rest of Asia Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Boston Scientific Corporation (U.S.), Medtronic (U.S.), Olympus (Germany), Stryker (U.S.), Biotronik. (Germany), Merit Medical Systems. (Utah), HealthTronics, Inc. (U.S.), Insightec (Israel), AngioDynamics (New York), Integra LifeSciences (U.S.), Bioventus LLC. (U.S.), Ethicon Inc. (U.S.), EDAP TMS (Auvergne-Rhône-Alpes), Sonablate Corp. (U.S.), BVM Medical (England), Terumo Europe NV (Belgium), and IceCure Medical (Israel)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global tumor ablation market is segmented into five notable segments such as type, types of treatment, cancer type, end users, and distribution channel.
- Based on type, the global tumor ablation market is segmented into thermal ablation, and chemical ablation
In 2023, the thermal ablation segment is expected to dominate the global tumor ablation market
In 2023, the thermal ablation segment is expected to dominate the market with a market share of 78.12% and growing with a CAGR of 13.9% in the forecast period of 2023 to 2030. It is expected to dominate the market due to its increasing demand among the population.
- Based on types of treatment, the market is segmented into percutaneous, laparoscopy, and surgical. In 2023, the percutaneous segment is expected to dominate the market with a market share of 56.32%, growing with a CAGR of 14.1% in the forecast period of 2023 to 2030
- Based on cancer type, the market is segmented into breast cancer, lung cancer, prostate cancer, liver cancer, kidney cancer, bone cancer, and others. In 2023, the breast cancer segment is expected to dominate the market with a market share of 33.50%, growing with a CAGR of 15.0% in the forecast period of 2023 to 2030
- Based on end users the market is segmented into hospitals, oncology centers, and others. In 2023, the hospitals segment is expected to dominate the market with a market share of 53.94%, growing with a CAGR of 13.9% in the forecast period of 2023 to 2030
- Based on distribution channel the market is segmented into direct tender and retail sales
In 2023, the direct tender segment is expected to dominate the global tumor ablation market
In 2023, the direct tender segment is expected to dominate the market with a market share of 57.20%, growing with a CAGR of 13.9% in the forecast period of 2023 to 2030. It is expected to dominate due to growing demand for tumor ablation procedures.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in global tumor ablation market are Boston Scientific Corporation (U.S.), Medtronic (U.S.), Olympus (Germany), Stryker (U.S.), Biotronik.(Germany), Merit Medical Systems.(Utah), HealthTronics, Inc.(U.S.), Insightec (Israel), AngioDynamics (New York), Integra LifeSciences (U.S.), Bioventus LLC.(U.S.), Ethicon Inc.(U.S.), EDAP TMS (Auvergne-Rhône-Alpes), Sonablate Corp.(U.S.), BVM Medical (England), Terumo Europe NV (Belgium), and IceCure Medical (Israel) among others.
Market Developments
- In June 2023, Merit Medical Systems. acquired Bluegrass Vascular’s Surfacer Inside-Out Access Catheter System. This will help the company to generate more revenues
- In June 2023, Sonablate Corp. was recognized as one of CEO View’s top 10 healthcare companies of the year 2023. This will help the company to establish its presence in the global tumor ablation market
- In November 2022, Terumo Europe NV announced that it welcomed the positive guidance released by the National Institute for Health and Care Excellence (NICE), mentioning that microwave ablation can be used provided standard arrangements are in place for clinical governance, consent, and audit. This is positive news as it broadens access to minimally invasive alternatives to surgery available to patients with symptomatic benign thyroid nodules
- In July 2022, EDAP TMS announced Focal One HIFU reimbursement raised to urology APC Level 6 under CMS Outpatient Prospective Payment System (OPPS) Proposed Rule for CY23. This helped the company to establish its global presence
- In July 2021, Bioventus LLC. and Misonix announced definitive agreement for Bioventus to acquire Misonix. This helped the company to strengthen its product portfolio
Regional Analysis
Geographically, the countries covered in the global tumor ablation market are, U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Rest of Asia Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Israel, Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant and the fastest-growing region in the global tumor ablation market during the forecast period of 2023 to 2030
North America is expected to dominate the market owing to the rising cases of cancer in U.S. and other countries of the region. North America will continue to dominate the market in terms of market share and revenue and flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and the launch of new products in this region. In addition, increasing demand for tumor ablation is expected to enhance this region's market growth rate further.
For more detailed information about the global tumor ablation market report, click here – https://www.databridgemarketresearch.com/reports/global-tumour-ablation-market
